205 related articles for article (PubMed ID: 35195514)
1. Effectiveness of 3 COVID-19 Vaccines in Preventing SARS-CoV-2 Infections, January-May 2021, Aragon, Spain.
Del Cura-Bilbao A; López-Mendoza H; Chaure-Pardos A; Vergara-Ugarriza A; Guimbao-Bescós J
Emerg Infect Dis; 2022 Mar; 28(3):591-598. PubMed ID: 35195514
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Residents of US Nursing Homes Before and During the Delta Variant Predominance, December 2020-November 2021.
Hatfield KM; Baggs J; Wolford H; Fang M; Sattar AA; Montgomery KS; Jin S; Jernigan J; Pilishvili T
Clin Infect Dis; 2022 Oct; 75(Suppl 2):S147-S154. PubMed ID: 35856635
[TBL] [Abstract][Full Text] [Related]
3. Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities, Spain.
Monge S; Olmedo C; Alejos B; Lapeña MF; Sierra MJ; Limia A;
Emerg Infect Dis; 2021 Oct; 27(10):2595-2603. PubMed ID: 34314670
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
5. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study.
Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Pályi B; Formanek-Balku E; Molnár GA; Herczeg R; Gyenesei A; Miseta A; Kollár L; Wittmann I; Müller C; Kásler M
Clin Microbiol Infect; 2022 Mar; 28(3):398-404. PubMed ID: 34838783
[TBL] [Abstract][Full Text] [Related]
6. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
Pattni K; Hungerford D; Adams S; Buchan I; Cheyne CP; García-Fiñana M; Hall I; Hughes DM; Overton CE; Zhang X; Sharkey KJ
BMC Infect Dis; 2022 Mar; 22(1):270. PubMed ID: 35307024
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Among Incarcerated People in California State Prisons: Retrospective Cohort Study.
Chin ET; Leidner D; Zhang Y; Long E; Prince L; Schrag SJ; Verani JR; Wiegand RE; Alarid-Escudero F; Goldhaber-Fiebert JD; Studdert DM; Andrews JR; Salomon JA
Clin Infect Dis; 2022 Aug; 75(1):e838-e845. PubMed ID: 35083482
[TBL] [Abstract][Full Text] [Related]
11. The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence.
Rosero-Bixby L
JMIR Public Health Surveill; 2022 May; 8(5):e35054. PubMed ID: 35483079
[TBL] [Abstract][Full Text] [Related]
12. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678
[TBL] [Abstract][Full Text] [Related]
13. Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021.
Lutrick K; Rivers P; Yoo YM; Grant L; Hollister J; Jovel K; Khan S; Lowe A; Baccam Z; Hanson H; Olsho LEW; Fowlkes A; Caban-Martinez AJ; Porter C; Yoon S; Meece J; Gaglani M; Burns J; Mayo Lamberte J; Nakayima Miiro F; Bissonnette A; LeClair L; Kutty PK; Romine JK; Stefanski E; Edwards LJ; Ellingson K; Gerald JK; Bedrick EJ; Madhivanan P; Krupp K; Gerald LB; Thompson M; Burgess JL
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1761-1765. PubMed ID: 34968373
[TBL] [Abstract][Full Text] [Related]
14. mRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021.
McLean HQ; McClure DL; King JP; Meece JK; Pattinson D; Neumann G; Kawaoka Y; Rolfes MA; Belongia EA
Influenza Other Respir Viruses; 2022 Jul; 16(4):607-612. PubMed ID: 35178857
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of BNT162b2 Vaccine Effectiveness in Galicia, Northwest Spain.
Pardo-Seco J; Mallah N; López-Pérez LR; González-Pérez JM; Rosón B; Otero-Barrós MT; Durán-Parrondo C; Rodríguez-Tenreiro C; Rivero-Calle I; Gómez-Carballa A; Salas A; Martinón-Torres F
Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409724
[TBL] [Abstract][Full Text] [Related]
16. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD
PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548
[TBL] [Abstract][Full Text] [Related]
17. Pfizer-BioNTech Coronavirus Disease 2019 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Long-term Care Facility Staff With and Without Prior Infection in New York City, January-June 2021.
Peebles K; Arciuolo RJ; Romano AS; Sell J; Greene SK; Lim S; Mulready-Ward C; Ternier A; Badenhop B; Blaney K; Real JE; Spencer M; McPherson TD; Ahuja SD; Sullivan Meissner J; Zucker JR; Rosen JB
J Infect Dis; 2023 Feb; 227(4):533-542. PubMed ID: 36626187
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States.
Tenforde MW; Patel MM; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; Gaglani M; McNeal T; Ghamande S; Shapiro NI; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Exline MC; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Gershengorn HB; Babcock HM; Kwon JH; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Olson SM; Stephenson M; Schrag SJ; Kobayashi M; Verani JR; Self WH;
Clin Infect Dis; 2022 May; 74(9):1515-1524. PubMed ID: 34358310
[TBL] [Abstract][Full Text] [Related]
19. Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum.
Kaura A; Trickey A; Shah ASV; Benedetto U; Glampson B; Mulla A; Mercuri L; Gautama S; Costelloe CE; Goodman I; Redhead J; Saravanakumar K; Mayer E; Mayet J
EClinicalMedicine; 2022 Apr; 46():101344. PubMed ID: 35295900
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021.
Yi S; Choe YJ; Kim J; Kim YY; Kim RK; Jang EJ; Lim DS; Byeon HR; Lee S; Park E; Kim SJ; Park YJ
Emerg Infect Dis; 2022 Mar; 28(3):753-756. PubMed ID: 35202529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
